Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine - PubMed (original) (raw)

Randomized Controlled Trial

Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine

Amy L Vincent et al. Vaccine. 2007.

Abstract

In the U.S., despite available swine influenza virus (SIV) vaccines, multiple influenza subtypes as well as antigenic and genetic variants within subtypes continue to circulate in the swine population. One of the challenges to control and eliminate SIV is that the currently used inactivated influenza virus vaccines do not provide adequate cross-protection against multiple antigenic variants of SIV in the field. We previously generated a recombinant H3N2 swine influenza virus (SIV) based on the influenza A/SW/TX/4199-2/98 virus (TX98) containing an NS1 gene expressing a truncated NS1 protein of 126 amino acids, TX98-NS1Delta126 virus. This recombinant strain was demonstrated to be highly attenuated in swine and showed potential for use as a modified live-virus vaccine (MLV) after intratracheal application in pigs. However, this route of inoculation is not practical for vaccination in the field. In the present study, we first compared intramuscular and intranasal routes of application of the MLV, and found that the intranasal route was superior in priming the local (mucosal) immune response. Pigs were then vaccinated via the intranasal route and challenged with wild type homologous TX98 H3N2 virus, with a genetic and antigenic variant H3N2 SIV (influenza A/SW/CO/23619/99 virus, CO99) and a heterosubtypic H1N1 SIV (influenza A/SW/IA/00239/2004 virus, IA04). The intranasally vaccinated pigs were completely protected against homologous challenge. In addition, MLV vaccination provided nearly complete protection against the antigenic H3N2 variant CO99 virus. When challenged with the H1N1 IA04 virus, MLV vaccinated animals displayed reduced fever and virus titers despite minimal reduction in lung lesions. In vaccinated pigs, there was no serologic cross-reactivity by HI assays with the heterologous or heterosubtypic viruses. However, there appeared to be substantial cross-reactivity in antibodies at the mucosal level with the CO99 virus in MLV vaccinated pigs.

PubMed Disclaimer

Figures

Fig. 1

Fig. 1

Mean rectal temperatures from 0 to 5 days post-infection (dpi) in pigs vaccinated 2 times via the intranasal route or non-vaccinated and challenged with homologous and heterologous viruses. Days post-infection are plotted along the X-axis. The cut-off for a febrile response was calculated as two standard deviations above the mean rectal temperature of 0 dpi and sham inoculated pigs from 0 to 5 dpi and is represented by the dashed horizontal line. *Statistical significance at p<0.05 was detected between the non-vaccinated IA04 challenged pigs compared to MLV vaccinated IA04 challenged pigs at 5 dpi.

Similar articles

Cited by

References

    1. Belshe RB. Current status of live attenuated influenza virus vaccine in the US. Virus Res. 2004 Jul;103(1–2):177–85. - PubMed
    1. Townsend HG, Penner SJ, Watts TC, Cook A, Bogdan J, Haines DM, et al. Efficacy of a cold-adapted, intranasal, equine influenza vaccine: challenge trials. Equine veterinary journal. 2001 Nov;33(7):637–43. - PubMed
    1. Belshe RB, Nichol KL, Black SB, Shinefield H, Cordova J, Walker R, et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5–49 years. Clin Infect Dis. 2004 Oct 1;39(7):920–7. - PubMed
    1. Buonagurio DA, O’Neill RE, Shutyak L, D’Arco GA, Bechert TM, Kazachkov Y, et al. Genetic and phenotypic stability of cold-adapted influenza viruses in a trivalent vaccine administered to children in a day care setting. Virology. 2006 Apr 10;347(2):296–306. - PubMed
    1. Chambers TM, Holland RE, Tudor LR, Townsend HG, Cook A, Bogdan J, et al. A new modified live equine influenza virus vaccine: phenotypic stability, restricted spread and efficacy against heterologous virus challenge. Equine veterinary journal. 2001 Nov;33(7):630–6. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources